 |
Biosketch
Curriculum Vitae
Name: Ian David Ramsay Arnott
Home Address: 31A Blackford Road,
Edinburgh,
EH9 2DT,
Telephone Number: 0131 667 7753
Date of Birth: 23rd July 1968
Nationality: British
Marital Status: Married
GMC number: 3679133
Defence society: MDDUS Membership number M101216
Business Address: Gastrointestinal Unit,
University of Edinburgh Department of Medical Sciences,
School of Clinical and Molecular Medicine,
Western General Hospital,
Edinburgh.
Telephone Number: 0131-537-3115
Fax: 0131-537-1007
Email: ian.arnott@luht.scot.nhs.uk
Education:
1977 - 1986 George Watson’s College, Edinburgh
1986 - 1989 St Andrews University
1st Year: Exemptions obtained from all terminal
examinations.
2nd Year: Passed with two first and two second rank
certificates.
3rd Year: Passed with two first and two second rank
certificates.
1989 - 1992 Manchester University
4th Year: Honours in surgery
Honours in Community Health
5th Year Elective experience gained in Malaysia.
Research project into industrial injury
and alcoholism.
Qualifications:
1989 BSc (Medical Science) St Andrews University
1992 MBChB Manchester University
1994 ACLS Certificate (renewed 2002)
1995 MRCP (UK)
1999 MD Manchester University
2006 FRCP (Edin)
Present Appointment
Consultant Gastroenterologist
Western General Hospital, Edinburgh
April 2003 until present
Previous Appointments:
Blinder Fellow
David Geffen School of Medicine at UCLA
University of California Los Angeles
Los Angeles, USA.
01.05.2003 – 30.04.2004
Specialist Registrar in Gastroenterology and General Medicine
South East Scotland Deanery
01.04.2001-31.03.2003
Western General Hospital, Edinburgh.
Gastroenterology
Consultants Prof J. Satsangi, Dr K.R. Palmer, Dr I.D. Penman, Dr. A.G. Shand, Dr J. Nimmo, Dr J. McKnight
01.10.2000-31.03.2001
Royal Infirmary of Edinburgh.
Hepatology
Consultants Prof. P.C. Hayes, Dr N.D.C. Finlayson, Dr R.C. Heading, Dr A. McGilchrist, Dr K. Simpson, Dr J. Plevris
01.09.99-31.09.00
Western General Hospital, Edinburgh
Gastroenterology
Consultants Dr K.R. Palmer, Dr. S. Ghosh, Dr I.D. Penman, Prof J. Satsangi
.
01.09.98-31.08.99
Victoria Hospital, Kirkcaldy
General Medicine
01.08.99-31.08.99 Diabetes
Consultant Prof. I.W. Campbell
01.05.99-31.07.99 Chest Medicine
Consultants Dr G.R. Petrie, Dr R.P. Smith
01.02.99-30.04.99 Coronary Care Unit
Consultant Dr C.M. Francis
1.11.98-31.1.98 Diabetes and Acute Geriatrics
Consultants Dr J.Chalmers, Dr S.B. Rochow
01.09.98-31.10.98 Cardiology
Consultant Dr C.M. Francis
01.02.1998 –31.08.1998
Western General Hospital, Edinburgh.
Locum Specialist Registrar in Gastroenterology
Consultants Prof A. Ferguson, Dr K.R. Palmer, Dr S. Ghosh, Dr I. Penman
Western General Hospital, Edinburgh.
February 1996 -January 1998
Clinical Research Fellow in Gastroenterology
Supervisors Professor A. Ferguson, Dr S. Ghosh
This post was primarily involved with the research necessary to complete my MD thesis although a number of other research projects were undertaken. The post also gave invaluable experience in areas such as clinical gastroenterology and endoscopy.
The main aim of my thesis has been to examine the use of intestinal permeability and whole gut lavage in assessing short to mid term prognosis in quiescent inflammatory bowel disease.
Manchester Royal Infirmary
August 1995 -January 1996
SHO in General medicine and Gastroenterology
Consultant: Dr J M Braganza, Dr T W Warnes
Blackburn Hospitals Medical Rotation
February 1995 - July 1995
SHO in General Medicine and Gastroenterology
Consultant Dr D A F Lynch
November 1994 - January 1995
SHO in General Medicine, Care of the Elderly and Coronary Care.
Consultant Dr N A Roberts
August 1994 - October 1994
SHO in General Medicine and Chest diseases
Consultants: Dr L Ormerod, Dr N Horsefield
February 1994 - July 1994
SHO accident and Emergency
Consultant: Mr J C Adams
August 1993 - January 1994
SHO in General Medicine and Cardiology
Consultant: Dr K.C. Hearn
August 1992 - January 1993
HO in General Medicine, Chest Disease and Neurology
Consultants: Prof. D Neary, Dr W Schady, Dr C C Hardy
January 1993 – July 1993
HO in General Surgery, Vascular Surgery and Urology
Consultants: Mr M.G. Walker, Mr R.W. Johnston
Clinical Experience
Gastroenterology
I have trained in all aspects of gastroenterology during time spent at the GI unit at the Western General Hospital and the Centre for liver and digestive disorders at the Royal Infirmary of Edinburgh. My specific clinical interests are as follows.
• Inflammatory Bowel Disease
The western general hospital has in international reputation for the care of patients with inflammatory bowel disease. I have developed a specific interest in IBD and the management of these patients encompasses a significant component of my clinical workload. There is a depth of experience in all areas, such as the initiation of third line treatments and selection of patients for surgery. There are also multidisciplinary meeting to discuss the management of these patients and I have also established a clinical meeting to discuss management problems of IBD patients reviewed at the outpatients clinic. I have a growing experience with newer treatment modalities, such as infliximab, of which the western general has one of the biggest single centre experience in the United Kingdom. IBD related clinical research is an established part of clinical practice. I also take part in a paediatric to adult transition clinic which aims to smoothly move individuals from paediatric to adult care.
• Upper GI Cancer
The western general also has a strong interest in upper gastrointestinal cancer. The diagnosis, staging and management of patients with dyspagia is also a component of my clinical workload. I participate in the multidisciplinary team where all cases are discussed and management plans formulated.
• Upper GI Bleeding
The western general also has a long history of excellence in the management of upper GI bleeding. I actively participate in the management of these patients including therapeutic endoscopy.
• Other Clinical Experience
I also have clinical experience in the management of patients with acute and chronic liver disease.
I have an ongoing on-call commitment to the GI unit of 1 in 5 for all gastrointestinal acute admissions. Common admissions include decompensated liver disease, upper GI cancer, active inflammatory bowel disease and gastrointestinal bleeding.
• Management Experience
Management is an important part of hospital practice. I have first hand experience constructing on-call rotas and organising local clinical meetings. I have also been the trainee representative on the Joint Committee for Higher Medical Training for the Royal College of Physicians of Edinburgh and the Royal College of Physicians and Surgeons of Glasgow. This has allowed a great insight in to these aspects of training, assessment and management.
Endoscopy
My first introduction to endoscopy was at Blackburn Royal Infirmary. I have gained experience in Manchester and more recently at the Western General Hospital and Royal Infirmary. I now have competency in upper GI endoscopy, enteroscopy, flexible sigmoidoscopy and colonoscopy. I also copetent at the therapeutic procedures of upper and lower laser therapy for vascular lesions and tumours, oesophageal dilatation, oesophageal stenting, colonic stenting, balloon dilatation, polypectomy and gastrostomy tube insertion.
Whilst in Los Angeles I was able to train in Video capsule endoscopy and now offer this as a routine clinical service at the western general hospital.
Procedures
Gastrointestinal Endoscopy
Diagnostic Upper Endoscopy
Therapeutic Upper Endoscopy Treatment of Bleeding Ulcers
Treatment of Oesophageal Varices
Oesophageal and pyloric Dilatations
Laser Therapy
Percutaneous Endoscopic Gastrostomy placement
Diagnostic and therapeutic Colonoscopy
Flexible Sigmoidoscopy
Enteroscopy
Endoscopic mucosal resection
Video capsule endoscopy
Research
MD Thesis
The main aim of my thesis was to examine the use of intestinal permeability and whole gut lavage in assessing short to mid term prognosis in quiescent inflammatory bowel disease.
Intestinal permeability was assessed using the differential urinary excretion of lactulose and rhamnose. In a separate patient group IL-1(, IL-8 and granulocyte elastase were assayed in whole gut lavage fluid as sensitive markers of intestinal inflammation.
Results from both studies have been presented at the British Society of Gastroenterology meeting in March 1998 and at the American Gastroenterological Association meeting in New Orleans in May 1998 and subsequently published in peer review journals. A significant relationship between relapse and abnormal intestinal permeability has been demonstrated. In a separate cohort of patients a further significant relationship between relapse and elevated gut lavage IL-1, IL-8 and granulocyte elastase has been shown.
Variation in gut lavage inflammatory markers with different anatomical disease distributions and the relationship of a clinical remission to a mucosal remission were areas also studied.
Many laboratory techniques including ELISA, HPLC and Radioimmunoassay have been involved together with the essential techniques of data processing, interpretation and statistical analysis.
Post Doctoral Research
1. Genetics of Inflammatory Bowel Disease
NOD2 has recently been identified as an important inherited determinant in Crohn’s disease. In striking contrast to other published series we have recently found that mutations of NOD2 are not major determinants of susceptibility or disease behaviour in our population. We have also recently found that mutations of the Toll-like receptor 4 and CD14 genes are also not implicated in inflammatory bowel disease. I have phenotyped a cohort of Crohn’s disease patients, analysed much of the data and have experience of the PCR based genotyping used to identify the mutations. I would therefore hope to continue to investigate some of the rarer mutations in the NOD2 gene and also other potential susceptibility genes. We have also progressed this data to investigate some of the newer genetic determinants, eg IBD5, OCTN 1/2, DLG5 and MDR1.
2. MRC Trial of Postoperative Prophalaxis in Crohn’s Disease
This study supported by a £1.5M grant from the Medical Research Council will take place in 5 centres across Scotland to assess the value of 6-Mercaptopurine to prevent post-operative recurrence in Crohn’s disease. We hope that this will be the definitive study to assess this question. A number of trials have attempted this in the past, all with significant flaws. Recruitment will start in March 2007 and the study will run for 6 years.
3. The Proteomics of Acute Severe Ulcerative Colitis
This project, funded by the Chief Scientists Office of Scotland, will examine the use of SELDI-TOF to assess the expressed protein profiles in patients with acute severe ulcerative colitis. We will specifically examine differences between those who where steroid responsive and those who are steroid resistant. It is hoped that this will allow not only the discovery of biomarkers but also novel insights in to the pathogenesis of steroid resistant ulcerative colitis. A research fellow has been appointed and will start work on the project in March 2007
4. Novel Serological Markers in Crohn’s Disease
Antibodies against microbial antigens have recently been identified in Crohn’s disease in a North American population. I recently travelled to Cedars-Sinai Medical centre in Los Angeles with 150 samples from our cohort of Crohn’s disease patients. I performed the assays to assess OmpC and I2 together with the more established markers ASCA and ANCA. I found that the pattern of antibody positivity was broadly similar in a Scottish and North American population and that there were some novel phenotypic associations. Major interest lies in whether these markers will act as indicators of treatment response in Crohn’s disease however initial analysis also suggests that these antibodies may be a secondary phenomenon.
5. The Role of Infliximab in Clinical Practice
A prospective audit of the use of infliximab has been ongoing in the GI unit. We have found that despite marked differences in prescribing practice, levels of efficacy comparable to published North American and European data. An assessment of markers of response has indicated that smokers respond less well and those taking immunomodulators respond better. I have been extensively involved in the design of the study, data collection, analysis and writing. I am currently assessing whether genetic factors are of importance in response to infliximab. We are currently planning to investigate the pharmacoeconomics of the treatment of Crohn’s disease with Infliximab and assess the use of Infliximab in acute UC in the Edinburgh cohort.
6. Collagenous Colitis
The treatment of Collagenous colitis, a condition characterised by watery diarrhoea, is often based on corticosteroids. Patients often respond poorly, need relatively high doses and often relapse when the treatment is stopped. We are currently investigating markers of treatment response in a cohort identified in South East Scotland. I have been involved in the patient identification and data collection. In a continuation of the above study we would also hope to collect DNA form the above cohort to study the presence of the genetic markers in Collagenous colitis.
We are also following up our work on ischaemic colitis. I am prospectively collecting a data set on patients with an acute abdomen in an attempt to find a serum marker indicative of ischaemic damage to the gut.
7. Video Capsule Endoscopy
I trained in capsule endoscopy at UCLA. The technology is soon to be available in Edinburgh and working together with collegues at the Royal Infirmary of Edinburgh a clinical service is being established together with the structure to enable research in to the use of this technology in patients with inflammatory bowel disease.
Clinical trials
I have been involved in a number of multi-centre clinical trials at the initiation and completion stages. I have also been involved in the initiation of 3 phase 2 and 3 company sponsored trials at UCLA. I have also been responsible for the running of 4 clinical trials which are;
1. A study of Certolizumab in Crohn’s patients refractory to Infliximab
2. Colalpred study. The use of a low bioavailability steroid in ulcerative colitis.
3. Leukine study. The use of GM-CSF in patients with active Crohn’s disease
4. RDP58 study. Examination of the use of this weak TNF inhibitor in patients with refractory ulcerative colitis.
5. The use of Infliximab in refractory ulcerative colitis
6. The use of pegylated TNF in active Crohn’s disease.
7. Matrix - A 2-year, randomised trial investigating the use of prednisolone or Budesonide in the treatment of Crohn’s disease and their effects on bone mineral density.
8. Freedom - A randomised trial investigating the use of either a fixed or a variable dose of Budesonide in the maintenance of remission in Crohn’s disease.
Teaching and Education
There is an integrated education programme within the gastrointestinal unit in Edinburgh. This included journal clubs (clinical and scientific), X-ray and histopathology meetings. In addition I attended hospital grand rounds.
I enjoy teaching and have a formal commitment to teach final year students on a weekly basis. I have previously been extensively involved in teaching medical students, House Officers and Senior House Officers at the bedside and in lecture format.
I teach at the Royal college of physicians MRCP part II written course in Edinburgh.
I am on the MRCP(UK) speciality question group for gastroenterology.
I am the educational supervisor of the foundation year 1 and senior house officers that are attached to our unit.
I have previously been the trainee representative at the JCHMT for the SAC in general medicine and on the central JCHMT committee.
Audit
Audit currently forms an important role in our clinical practice. The audits I have undertaken are:
1. A retrospective audit of patients undergoing colectomy for acute ulcerative colitis in our unit over the last five years. It has been useful to assess the total number of procedures but also to assess timing, prior treatment and pathological appearances of the specimens.
2. The use of infliximab is being prospectively audited in the unit. The initial experience has recently been published. This idea has been extended to assess whether treatment affects hospital visits of admissions. Changes to practice have included the pre-treatment with hydrocortisone and a more rigorous adherence to the NICE guidelines.
3. Deaths in the GI unit, 1998-1999. Western General Hospital. The largest cause of death on our ward was oesophageal cancer, which reflected the workload. The second was end stage liver disease. Changes to practice included a more formal transfusion protocol and when to proceed to TIPSS.
4. Medical readmission over the last year in the Victoria Hospital, Kirkcaldy. 1999. Although an increased rate of readmission within 28 days was seen, no obvious factors were identified.
5. The use of nebulised bronchodilators in acute asthma.1995 Queens Park Hospital Blackburn. This study demonstrated continuing inappropriate use of anticholinergic bronchodilators in young asthmatic patients.
Courses Attended
November 1996 Elementary data analysis course, University of Edinburgh.
November 1997 Third advanced gastroenterology course, Royal College of Physicians, Edinburgh.
May 1998 American Society of Gastrointestinal Endoscopy, Postgraduate Course, New Orleans, USA.
December 1998 Gastrointestinal and liver disease, Royal College of Physicians, Edinburgh.
November 1999 Management training for specialist registrars-Negotiation skills. The Lister Postgraduate Institute, Edinburgh.
March 2002 Resuscitation training course, Western General Hospital, Edinburgh.
June 2002 Adult medical emergencies for consultants course, The Lister Postgraduate Institute, Edinburgh
November 2002 Professional development programme: Legal and ethical issues. The Lister Postgraduate Institute, Edinburgh.
November 2002 Problems in management course. The Lister Postgraduate Institute, Edinburgh.
December 2002 The Lister professional certificate in medical education. The Lister Postgraduate Institute, Edinburgh
April 2003 Third international IBD Meeting, Capri, Italy.
June 2006 Train the trainer colonoscopy course. Glasgow Royal Infirmary, Glasgow.
Publications
MD Thesis
Arnott IDR. Gut mucosal inflammation in inflammatory bowel disease: Relevance to short term prognosis. University of Manchester, June 1999.
Book Chapters
1. Ghosh S, Drummond HE, Dahale A, Hoque SS, Arnott IDR. Marsh MM, editors. Celiac Disease: Methods and protocols. Totowa, New Jersey: Humana Press; 2000; 18, Whole gut lavage fluid analysis: A minimally invasive method for study of mucosal immunity and inflammation. p. 257-77.
2. Colombel JF, Ferrari N, Arnott IDR, Libersa C, Satsangi J. Pharmacogenetics and IBD. In: Satsangi J, Sutherland LR, editors. Allan's Inflammatory Bowel Diseases. London: Churchill Livingstone, 2003
3. Arnott IDR, Satsangi J. Clinical, Molecular and Serological Sub-typing of the Manifestations of Crohn’s Disease. IBD yearbook. In press.
4. Noble CL, Arnott IDR. Emerging Treatment Modalities in Inflammatory Bowel Disease. In: Modern therapeutics in clinical practice. In press.
5. Noble CL, Arnott IDR. What is the risk that a child will develop inflammatory bowel disease if one or both parents have inflammatory bowel disease? In: Questions in inflammatory bowel disease. In Press.
Original Papers
1. Arnott IDR, Ghosh S, Ferguson A. The spectrum of Ischaemic Colitis. European Journal of Gastroenterology and Hepatology. 1999 Mar;11(3):295-303.
2. Arnott IDR, Ghosh S. Portal hypertension in the presence of minimal liver damage in Crohn’s disease on long term azathioprine: possible endothelial cell injury. European Journal of Gastroenterology and Hepatology. 2000 May;12(5):569-73.
3. Arnott IDR, Kingstone K, Ghosh S. Abnormal intestinal permeability predicts relapse in patients with inactive Crohn’s disease. Scandinavian Journal of Gastroenterology. 2000 Nov;35(11):1163-9.
4. Arnott IDR, Shand A, Ghosh S. Administration of Infliximab in Crohn’s Disease Does Not Deplete Complement Components C3 and C4. American Journal of Gastroenterology. 2000 Nov;95(11):3326-7
5. Arnott IDR, Drummond HE, Ghosh S. Gut Mucosal Secretion of Interleukin-1 and Interleukin-8 Predict Relapse in Clinically Inactive Crohn’s Disease. Digestive Diseases and Sciences. 2001 Feb; 46(2):402-11
6. Arnott IDR, Drummond HE, Ghosh S, Ferguson A. Gut luminal neutrophil migration varies with anatomical site of Crohn’s disease. European Journal of Gastroenterology and Hepatology. 2001 Mar; 13(3):239-43
7. Arnott IDR, MacDonald D, Williams A, Ghosh S. Clinical Use of Infliximab in Crohn’s Disease: The Edinburgh Experience. Alimentary Pharmacology and Therapeutics 2001 Oct;15(10):1639-46.
8. Wong NACS, Arnott IDR, Pope I, Palmer KR, Garden OJ, Thomas JStJ, Piris J. Hepatobiliary cystadenomas with mesenchymal stroma may mimic biliary smooth muscle neoplasms – a study with smooth muscle and hormone receptor immunohistochemistry. Histopathology 2001 Nov;39(4):434-436.
9. Arnott IDR, Drummond HE, Ghosh S. Frequency of subtle mucosal inflammation in clinically inactive Crohn’s disease. Scottish Medical Journal. 2001 Nov; 46(5):136-139.
10. Shen EF, Arnott IDR, Plevris J, Penman ID. Endoscopic Ultrasonography in the Diagnosis and Management of Upper Gastrointestinal Submucosal Tumours. British Journal of Surgery. 2002 Feb 89(2):231-235.
11. Arnott IDR, Gillett HR, McIntyre M, Campbell S, Dahele A, Priest M, Jackson R, Ghosh S. Successful infliximab treatment for steroid-refractory celiac disease: a case report.Gastroenterology. 2002 Mar;122(3):800-5.
12. Arnott IDR, Watts D, Ghosh S. Review article: is clinical remission the optimum therapeutic goal in the treatment of Crohn's disease? Alimentary Pharmacology and Therapeutics. 2002 May;16(5):857-67.
13. Arnott IDR, Shand AJ. Meeting report: British Society of Gastroenterology annual meeting. Inflammatory bowel diseases monitor. 2002 June;3(4):159-60.
14. Arnott IDR, Williams N, Drummond HE, Ghosh S. Whole Gut Lavage Fluid IL-1 and IL-8 in Smokers and Non-Smokers with Crohn’s Disease in Clinical Remission. Digestive and Liver Disorders. 2002 July 34(7):424-9
15. Arnott IDR, Watts D, Satsangi J. Azathioprine and Anti-TNF therapies in Crohn’s Disease: A Review of Pharmacology, Clinical Efficacy and Safety. Pharmacological Research. 2003 Jan 47(1):1-10.
16. Arnott IDR, Satsangi J. Crohn’s disease or Crohn’s diseases? Gut 2003 Apr 52(4):460-1.
17. Probert CSJ, Hearing SD, Schreiber S, Kühbacher T, Ghosh S, Arnott IDR, Forbes A. Infliximab in steroid-resistant ulcerative colitis – a randomised controlled trial. Gut 2003 Jul;52(7):998-1002.
18. Arnott IDR, McNeill G, Satsangi J. An Analysis of Factors Influencing Short-Term and Sustained Response to Infliximab Treatment for Crohn’s Disease. Alimentary Pharmacology and Therapeutics. 2003 Jun 15;17(12):1451-7
19. WalkerLJ, Aldhous MC, Drummond HE, Smith BKR, Nimmo ER, Arnott IDR, Satsangi J. Anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn’s disease are associated with disease severity but not NOD2/CARD15 mutations. Clinical and Experimental Immunology. 2004 March;135(3):490-496
20. Arnott IDR. Complementary therapies in inflammatory bowel disease: use is widespread but more evidence of efficacy is needed. Evidence-Based Gastroenterology. 5(2):52-53, May 2004.
21. Arnott IDR, Nimmo ER, Drummond HE, Fennel J, Smith BKR, MacKinlay E, Morecroft J, Anderson N, Kelleher D, O’Sullivan M, McManus R, Satsangi J. NOD2/CARD15, TLR4 and CD14 mutations in Scottish and Irish Crohn's disease patients: evidence for genetic heterogeneity within Europe? Genes Immun. 2004 Jul;5(5):417-25
22. Arnott IDR, Satsangi J. Genotype-phenotype relationships in Crohn’s disease. Inflammatory Bowel Disease Monitor. 2004 July; 5(4):122-127
23. Arnott IDR, Lo SK. The Clinical Utility of Wireless Capsule Endoscopy. Digestive Diseases and Sciences. 2004 Jun;49(6):893-901.
24. Smith BKR, Arnott IDR, Drummond HE, Nimmo ER, Satangi J. Disease Location, Anti-Saccharomyces Cerevisiae Antibody (ASCA) and NOD2/CARD15 Genotype Influence the Progression of Disease Behaviour in Crohn’s Disease. Inflammatory Bowel Diseases. 2004 September;10(5):521-528.
25. Arnott IDR, Landers CJ, Nimmo EJ, Drummond HE, Smith BKR, Targan SR, Satsangi J. Sero-Reactivity to Microbial Components in Crohn’s Disease is Associated with Disease Severity and Progression, but Not NOD2/CARD15 Genotype. American Journal of Gastroenterology. 2004 December;99(12): 2376–2384.
26. Arnott IDR, Ho GT, Nimmo ER, Satsangi J. Toll-like receptor 4 gene in IBD: further evidence for genetic heterogeneity in Europe. Gut. 2005 Feb;54(2):308
27. Ho GT, Nimmo ER, Tenesa A, Fennell J, Drummond H, Mowat C, Arnott IDR, Satsangi J. Allelic variations of the multidrug resistance gene determine susceptibility and disease behavior in ulcerative colitis. Gastroenterology. 2005 Feb;128(2):288-96
28. Noble CL, Nimmo ER, Drummond H, Smith L, Arnott IDR, Satsangi J. DLG5 variants do not influence susceptibility to inflammatory bowel disease in the Scottish population. Gut. 2005 Apr 20; [Epub ahead of print]
29. Quan C, Chen G, Lee-Henderson M, Kalpakian M, Chan S, Tran T, Enayati P, Dulai G, Kitahara F, Arnott IDR, Sul J, Jutabha R. Overtube-assisted placement of wireless capsule endoscopy device.Gastrointest Endosc. 2005 Jun;61(7):914-6.
30. Noble CL, Nimmo ER, Drummond H, Ho GT, Tenesa A, Smith L, Anderson N, Arnott IDR, Satsangi J.Analysis of the contribution of OCTN1 / 2 variants within the IBD5 locus to disease susceptibility and severity in Crohn’s disease. Gastroenterology. In press.
31. Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, Caprilli R, Colombel JF, Gasche C, Geboes K, Jewell DP, Karban A, Loftus Jr EV, Pena AS, Riddell RH, Sachar DB, Schreiber S, Steinhart AH, Targan SR, Vermeire S, Warren BF. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005 Sep;19 Suppl A:5-36.
32. Noble CL, Nimmo ER, Drummond H, Ho GT, Tenesa A, Smith L, Anderson N, Arnott ID, Satsangi J. The contribution of OCTN1/2 variants within the IBD5 locus to disease susceptibility and severity in Crohn's disease. Gastroenterology. 2005 Dec;129(6):1854-64.
33. Lees CW, Shand AG, Penman ID, Satsangi J, Arnott ID. Role of infliximab in ulcerative colitis: further questions. Inflamm Bowel Dis. 2006 Apr;12(4):335-7.
34. Ho GT, Chiam P, Drummond H, Loane J, Arnott ID, Satsangi J. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther. 2006 Jul 15;24(2):319-30.
35. Ho GT, Soranzo N, Tate SK, Drummond H, Nimmo ER, Tenesa A, Arnott ID, Satsangi J. Lack of association of the pregnane X receptor (PXR/NR1I2) gene with inflammatory bowel disease: parallel allelic association study and gene wide haplotype analysis. Gut. 2006 Nov;55(11):1676-7.
Abstracts
1. Rajan JN, Noble CL, Anderson C, Satsangi J, Lessels AM, Arnott IDR. The epidemiology and clinical features of collagenous colitis in Lothian. Gut 2005;54: (Suppl)A99.
2. Noble CL, Nimmo ER, Dummond HE, Smith L, Arnott IDR, Satsangi J. OCTN1 and 2 polymorphisms within the IBD5 locus predict susceptibility and severity in Crohn’s disease. Gut 2005;54: (Suppl)A96.
3. Aldhous MC, Drummond HE, Arnott IDR, Smith L, Satsangi J. Effect of smoking habit and load on clinical presentation and progression in Crohn’s disease and ulcerative colitis. Gut 2005;54: (Suppl)A2.
4. Arnott IDR, Smith BKR, Drummond HE, Nimmo ER, Satsangi J. Disease Location, Anti-Saccharomyces Cerevisiae Antibody (ASCA) and NOD2/CARD15 Genotype Influence the Progression of Disease Behaviour in Crohn’s Disease. Gastroenterology 2004, A-109.
5. Arnott IDR, Li C, Shintaku P, McGowan I, Anton P, Braun J. Is deposition of split complement fraction C4d a marker of antibody mediated gut damage in inflammatory bowel disease. Gastroenterology 2004, A-289
6. Dring M, Satsangi J, Arnott IDR, Ho GT, Kelleher D, McManus R. Multidrug resistance gene (MDR-1) polymorphisms in a refractory Crohn’s disease population. Gastroenterology 2004, A-489.
7. Chen G, Chan S, Quan C, Kalpakian M, Tran T, Enayati P, Henderson ML, Dulai GS, Arnott IDR, Kitahara F, Gornbein J, Jutabha R. Sensitivity and inter-observer variability for capsule endoscopy image analysis in a cohort of novel readers. Gastroenterology 2004, A-538.
8. Chan S, Chen G, Kalpakian M, Quan C, Henderson ML, Tran T, Enayati P, Dulai GS, Arnott IDR, Kitahara F, Gornbein J, Jutabha R. Factors that deley transit time of wireless capsule endoscopy. Gastroenterology 2004, A-544
9. Arnott IDR, Smith BKR, Drummond HE, Nimmo ER, Satsangi J. Should perianal Crohn’s disease be classified as penetrating disease (B3) by the Vienna Classification? Gastroenterology 2004, A-689.
10. Arnott IDR, Landers CJ, Targan SR, Satsangi J. Incidence and Phenotypic Associations of Novel Antibody Markers in Crohn’s Disease. Gastroenterology 2003.
11. Nimmo ER, Arnott IDR, Drummond HE, MacKinlay E, Morecroft J, Hutchinson J, Satsangi J. Mutations of Toll-Like Receptor 4 and CD14 Genes are Not Associated With Susceptibility or Disease Behaviour in Inflammatory Bowel Disease. Gastroenterology 2003
12. Arnott IDR, MacNeill G, Satsangi J. Azathioprine and Smoking Status in Crohn’s Disease Predict Response to Infliximab. Gastroenterology 2003
13. Nimmo ER, Arnott IDR, Drummond HE, MacKinlay E, Morecroft J, Hutchinson J, Satsangi J. Mutations of Toll-Like Receptor 4 and CD14 Genes are Not Associated With Susceptibility or Disease Behaviour in Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2003
14. Arnott IDR, Landers CJ, Targan SR, Satsangi J. Incidence and Phenotypic Associations of Novel Antibody Markers in Crohn’s Disease. Gut 2003.
15. Nimmo ER, Arnott IDR, Drummond HE, MacKinlay E, Morecroft J, Hutchinson J, Satsangi J. Mutations of Toll-Like Receptor 4 and CD14 Genes are Not Associated With Susceptibility or Disease Behaviour in Inflammatory Bowel Disease. Gut 2003
16. Arnott IDR, MacNeill G, Satsangi J. Azathioprine and Smoking Status in Crohn’s Disease Predict Response to Infliximab. Gut 2003
17. Crichton DN, Arnott IDR, Watts D, Mowat C, Drummond HE, Hutchinson J, Satsangi J. Nod2/CARD15 mutations in a Scottish Crohn's disease population. Gastroenterology 122 (4): M1420 Suppl. 1 Apr 2002.
18. Arnott IDR, Ghosh S. Treatment of Crohn's disease with infliximab does not reduce hospital attendance or admission. Gastroenterology 122 (4): M899 Suppl. Apr 2002. (Plenary poster)
19. Crichton DN, Arnott IDR, Watts D, Mowat C, Drummond HE, Hutchinson J, Satsangi J. Nod2/CARD15 mutations in a Scottish Crohn's disease population. Gut 2002;50: 266 Suppl.
20. Arnott IDR, Ghosh S. Treatment of Crohn's disease with infliximab does not reduce hospital attendance or admission. Gut 2002;50: 168 Suppl.
21. Arnott IDR, Shen EF, Zarins K, Plevris J, Penman ID. Inaccurate EUS Staging of Oesophageal Cancer: Assessment of Causality. [Abstract] Gastrointestinal Endoscopy 2001;53: 4149 Suppl.
22. Arnott IDR, Campbell S, Dahele1A, McIntyre M, Ghosh S. Successful Infliximab Treatment For Steroid Refractory Coeliac Disease. [Abstract] Gastroenterology 2001;120: 2008 Suppl.
23. Arnott IDR, Ghosh S. Audit of anti-TNF antibodies in clinical practice. [Abstract] Gut 2001;48: (Supp1)069 (plenary poster)
24. Arnott IDR, Campbell S, Dahele1A, McIntyre M, Ghosh S. Successful Infliximab Treatment For Steroid Refractory Coeliac Disease. [Abstract] Gut 2001;48: (Supp1)299
25. Arnott IDR, Humphreys KA, Ghosh S. Low Whole Gut lavage Fluid Complement C3 predicts Poor Outcome in Inactive Crohn’s Disease. [Abstract] Gut 2000;46: (Suppl)A234
26. Arnott IDR, Ghosh S. Jejunal biopsy abnormalities in collagenous colitis: associated coeliac disease? [Abstract] Gut 1999;Suppl V:A302
27. Arnott IDR, Drummond H, Ghosh S. Clinical features but not serum markers predict relapse in patients with inactive Crohn's disease. [Abstract] Gut 1999;44:(Suppl 1)A34
28. Arnott IDR, Williams N, Drummond H, et al. Continuing mucosal inflammation in clinically inactive Crohn's disease is not determined by smoking habits. [Abstract] Gut 1999;44:(Suppl 1)A38
29. Arnott IDR, Ghosh S, Ferguson A. Abnormal intestinal permeability predicts relapse in patients with inactive Crohn's disease. [Abstract] Gastroenterology 1998;114, part 2:(4)G3785
30. Arnott IDR, Drummond HE, Ghosh S, et al. IL-1 and granulocyte elastase in whole gut lavage fluid predict relapse in patients with inactive Crohn's disease. [Abstract] Gastroenterology 1998;114, part 2:(4)G3787
31. Arnott IDR, Ghosh S, Ferguson A. Ischaemic colitis is not just a disease of elderly arteriopaths. [Abstract] Gastroenterology 1998;114, part 2:(4)G1425
32. Arnott IDR, Drummond HE, Ghosh S, et al. Gut luminal neutrophil migration depends on the anatomical site of Crohn's disease. [Abstract] Gastroenterology 1998;114, part 2:(4)G3786
33. Arnott IDR, Drummond HE, Ghosh S, et al. Gut luminal neutrophil migration depends on the anatomical site of Crohn's disease. [Abstract] Gut 1998;42:(Suppl 1)A9
34. Arnott IDR, Ghosh S, Ferguson A. Abnormal intestinal permeability predicts relapse in patients with inactive Crohn's disease. [Abstract] Gut 1998;42:(Suppl 1)A41
35. Arnott IDR, Drummond HE, Ghosh S, et al. IL-1 and granulocyte elastase in whole gut lavage fluid predicts relapse in patients with in active Crohn's disease. [Abstract] Gut 1998;42:(Suppl 1)A41
36. Arnott IDR, Ghosh S, Drummond HE, et al. Improvement in Whole Gut Lavage Inflammatory Markers in Patients with Crohn's Disease treated with Elemental Diet. [Abstract] Gut 1997;41:(Suppl 3)A225-P827
37. Arnott IDR, Ghosh S, Drummond H, et al. Crohn's disease patients in clinical remission show evidence of ongoing mucosal inflammation. [Abstract] Gut 1997;40:(Suppl 1)A23
38. Ghosh S, Arnott IDR, Drummond HE, et al. Gut Luminal Neutrophil Migration Depends on the Anatomical Site of Crohn's Disease. [Abstract] 9th International Congress of Mucosal Immunology: Workshop 1996;9:A109-W3.6.21
39. Arnott IDR, Drummond HE, Handy L, et al. Gut Luminal Neutrophil Migration Depends on the Anatomical site of Crohn's Disease. [Abstract] Gut 1996;39:(Suppl 1)A18
Presentations at Academic Meetings
1. Arnott IDR, Smith BKR, Drummond HE, Nimmo ER, Satsangi J. Disease Location, Anti-Saccharomyces Cerevisiae Antibody (ASCA) and NOD2/CARD15 Genotype Influence the Progression of Disease Behaviour in Crohn’s Disease. Digestive Diseases Week, New Orleans, USA. 18.05.2004.
3. Arnott IDR, MacNeill G, Satsangi J. Azathioprine and Smoking Status in Crohn’s Disease Predict Response to Infliximab. British Society of Gastroenterology, Annual Meeting, Brimingham 24.03.2003
4. Arnott IDR, McNeill G, Satsangi J. Predicting Response to Infliximab in Crohn’s Diseases. Scottish Society of Gastroenterology. 29.11.2002
5. Nimmo ER, Arnott IDR, Drummond HE, MacKinney E, Morecroft J, Hutchinson J, Satsangi J. An Analysis of NOD2, Toll-Like Receptor 4 and CD14 Genes in a Scottish Inflammatory Bowel Disease Population. Scottish Society of Gastroenterology. 29.11.2002
6. Arnott IDR, Walker L, Satsangi J. Novel Antibodies in Crohn’s disease: Incidence and phenotypic associations. The Scottish Society of Experimental Medicine. University of Edinburgh 22.11.2002
7. Arnott IDR, McNeill G, Satsangi J. Anti TNF Antibodies (Infliximab) in the Treatment of Crohn’s Disease. Western General Hospital Grand Round. 23.10.2002
8. Arnott IDR, McNeill G, McKinlay E, Moorecroft J, Satsangi J. Infliximab in Crohn’s disease: Efficacy, cost and prediction of relapse. Scottish Society of Physicians. Royal College of Physicians of Edinburgh 28.9.2002
9. Arnott IDR, Lessels A, Penman ID, Shanahan F. Clinico-pathological conference. Enteropathy associated T-cell lymphoma. Western General Hospital Grand Round. 26.09.2001
10. Arnott IDR, Lessels A, Penman ID, Shanahan F. Clinico-pathological conference. Enteropathy associated T-cell lymphoma. GI Unit 50th Anniversary. 21.09.2001
11. Arnott IDR, Ghosh S. An Audit of the Use of Infliximab in Clinical Practice. Caledonian Society of Gastroenterology: 17.11.2000
12. Shen EF, Arnott IDR, Plevris J, Penman ID. Endoscopic ultrasound in the management of upper gastrointestinal submucosal lesions. Caledonian Society of Gastroenterology: 17.11.2000.
13. Arnott IDR, Shand A, Ghosh S. Administration of Infliximab in Crohn’s Disease Does Not Deplete Complement Components C3 and C4. Caledonian Society of Gastroenteroloring Meeting, Harrogate, 12.3.98.
14. Arnott IDR, Ghosh S, and Ferguson A. Ischaemic Colitis is not Just a Disease of Elderly Arteriopaths. Caledonian Society of Gastroenterology: 21.11.97;
15. Arnott IDR, Ghosh S, and Ferguson A. Improvement in Whole Gut Lavage Inflammatory Markers in Patients with Crohn's Disease Treated with Elemental Diet. Caledonian Society of Gastroenterology: 6.6.97;
16. Arnott IDR, Drummond HE, Handy L, Ghosh S, Ferguson A. Gut Luminal Neutrophil Migration Depends on the Anatomical site of Crohn's Disease. British Society of Gastroenterology, Autumn meeting, Manchester: 19.9.96;
17. Arnott IDR, Warnes TW. Case presentation of 21 year old male who presented with a pulmonary blastoma. Manchester Royal Infirmary Grand Rounds: 23.5.95;
Invited Lectures
1. Collagenous colitis: A case report and review of the literature.Western General Hospital Grand Rounds. Western General Hospital, Edinburgh 13.10.2004.
2. Novel biological therapies for the treatment of inflammatory bowel disease. Regional Gastrointestinal Clinical Meeting. Scotsman Hotel 28.10.2004.
3. Crohn’s disease: A western (general) prespective. Wishaw Hospital Clinical Meeting. Wishaw 28.01.2005.
4. Inflammatory bowel diseases. Scotland Advanced Medicine Conference for Consultant Physicians. Dalmahoy Hotel, Edinburgh 26/04/2005.
5. Inflammatory bowel disease. West of Scotland Gastrointestinal study day. Crosshouse Hospital, Kilmarnock 25.02.2005.
6. Novel therapies in inflammatory bowel disease. Royal College of Physicians Moving Points in Medicine. Ninewells Hospital, Dundee. 16.11.2005
7. Infliximab, where are we now? Course in gastroenterology and Hepatology, Royal College of Physicians, Edinburgh. 26.01.2006
8. Video capsule endoscopy: state of the art. Royal College of Physicians. 23.08.2006
9. Update on gastrointestinal bleeding. Liberton Hospital Medical Meeting. 29.06.2006
10. Case presentation at the Masterclass in inflammatory bowel disease meeting. Newcastle. 04.10.2006
Committees and Additional Positions Held
2006 Organiser of Scottish Society of Gastroenterology Winter meeting. National Galleries for Scotland. 01.12.2006
2006 – Editorial board, IBD Monitor
2006 – 2009 Member of MRCP(UK) speciality question group in Gastroenterology.
2006 – 2007 Medical Editor, NACC news, National Association of Crohn’s and colitis quaterly newletter.
2005 Royal College of Physicians of Edinbugh gastroenterology symposium sub committee member.
2001 – 2003 Trainee representative for Edinburgh and Glasgow Royal College of Physicians on the Joint Committee of Higher Medical Training.
2000 – 2003 Trainee representative for Edinburgh and Glasgow Royal College of Physicians on the Specialist Advisory Committee in General Medicine to Joint Committee of Higher Medical Training.
2002 – 2003 Study leave appeals panel-Trainee representative. Lister Postgraduate Institute, Edinburgh.
1998 - 1999 Junior representative of local negotiating committee, Kirkcaldy acute hospitals NHS trust.
1998 -1999 Chairman of Junior Doctors committee, Victoria Hospital, Kirkcaldy.
1996 - 1997 GI laboratory, Clinical trials study group co-ordinator, Western General Hospital.
1991 - 1992 Vice President and Social Convenor of Manchester Royal Infirmary Mess Committee.
1987 - 1988 St Andrews Bute Medical Society Charities Convenor
1986 - 1987 First year representative - Bute Medical Society
St Andrews University.
1985 - 1986 School Prefect - George Watsons College
Captain of 2nd Rugby XV.
1984 – 1985 Secretary - junior section - Merchants of Edinburgh
Golf Club.
Other Academic Activities
I referee scientific papers for Gut, Lancet, Alimentary Pharmacology and Therapeutics, Drugs, American Journal of Gastroenterology, Inflammatory Bowel Diseases, Digestive and Liver Diseases
I am a member of the British Society of Gastroenterology, American gastroenterological association and the Scottish Society of Gastroenterology
I am a finals examiner for the University of Edinburgh, MBChB course
General Interests
Golf Keen participant. Present handicap 12
Skiing Skied for school 1985
Skied for University 1986
I also enjoy cycling and hill walking.
Other Interests Reading, Current affairs, Travel.
|